Shares of Moderna fell 4.23% to $150.61 at 11:07 EST on Friday, after two sequential sessions in a row of gains. The Nasdaq Stock Market is rising 0.3% to $12,414.80, following yesterday's upward trend, on what as yet seems, a somewhat positive trend exchanging session today.
Moderna's last close was $157.26, 18.52% under its 52-week high of $178.50.
News about Moderna today
Moderna expects to provide up to 125 mln covid-19 vaccine doses globally in q1. According to today's article on Business Insider, "Moderna said Thursday that it expects to have between 100 million and 125 million doses of its potential COVID-19 vaccine available globally in the first quarter of 2021, with 85 million-100 million of those available in the U.S"
Moderna to provide israel health ministry with additional 4 million doses of its covid-19 vaccine candidate. According to today's article on MarketWatch, "Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273"
Moderna's Sales
Moderna's sales growth is 1428.1% for the present quarter and 12348.6% for the next. The company's growth estimates for the ongoing quarter is a negative 48.6% and positive 528.6% for the next.
Moderna's Revenue
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna's Stock Top and Bottom Yearly Value
Moderna's stock is valued at $150.61 at 11:07 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.68.
Moderna's Moving Average
Moderna's worth is way above its 50-day moving average of $88.87 and way higher than its 200-day moving average of $73.28.
Previous days news about Moderna
Moderna to ask FDA to authorize vaccine. According to The Wall Street Journal on Mon Nov 30, "Moderna will ask U.S. and European health regulators today to authorize use of its Covid-19 vaccine after it was previewn to be 94.1% effective in a full analysis of a pivotal study, keeping it on track to go into use in the U.S"
According to Bloomberg Quint on Mon Nov 30, "Moderna Plans to Seek U.S., EU Clearance for Covid Vaccine."
Moderna to file EUA for coronavirus vaccine candidate, which previewed 94.1% efficacy. According to MarketWatch on Mon Nov 30, "Moderna Inc. said Monday that it will file for emergency use authorization from the Food and Drug Administration for its coronavirus vaccine candidate, mRNA-1273"
According to MarketWatch on Mon Nov 30, "Moderna shares soar 11% on filing for emergency-use authorization for vaccine."
Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to CNBC on Mon Nov 30, "Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more.."
Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to CNBC on Mon Nov 30, "Moderna shares rereport on strong efficacy data."
According to Bloomberg Quint on Mon Nov 30, "Moderna Seeks Approval; WHO Spotlights Risks: Virus Update."
Moderna mania draws bitcoin comparisons while shorts bleed. According to Bloomberg Quint on Tue Dec 1, "Moderna Mania Draws Comparisons to Bitcoin While Shorts Bleed."
According to Bloomberg Quint on Wed Dec 2, "Moderna Falls After Merck Sells Stake in the Vaccine Maker."
According to Bloomberg Quint on Wed Dec 2, "Astra Data, Novavax Delay Spur Moderna Vaccine Demand, CEO Says."
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
